<DOC>
	<DOCNO>NCT00003279</DOCNO>
	<brief_summary>RATIONALE : Vaccines may help body build immune response kill tumor cell . PURPOSE : Randomized phase III trial compare effectiveness vaccination monoclonal antibody BEC2 BCG therapy treat patient limited-stage small cell lung cancer .</brief_summary>
	<brief_title>Vaccination Therapy Treating Patients With Limited-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine impact adjuvant monoclonal antibody BEC2 BCG survival patient limited stage small cell lung cancer . II . Determine safety regimen patient . III . Determine progression-free survival quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord center , Karnofsky performance status ( 60-70 % vs 80-100 % ) , response first-line combined modality treatment ( complete vs partial ) . Within 3-7 week completion prior induction chemoradiotherapy , respond patient randomize 1 2 treatment arm . Arm I : Patients receive best supportive care observe disease progression document . Arm II : Patients receive adjuvant monoclonal antibody BEC2 BCG intradermally day 1 week 0 , 2 , 4 , 6 , 10 . Treatment consist 5 vaccination period 10 12 week absence unacceptable toxicity disease progression . Quality life assess baseline , week 6 , 12 , 24 , every 6 month thereafter . Patients follow every 3 month . PROJECTED ACCRUAL : Approximately 500 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven limited stage small cell lung cancer ( SCLC ) Must complete adequate firstline combine modality treatment comprise least 46 course 2drug chemotherapy regimen chest radiotherapy No evidence disease progression relapse Disease response ( complete partial ) treatment PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm3 Platelet count great 100,000/mm3 Hepatic : AST le 1.5 time upper limit normal Hepatitis B negative Renal : Not specify Cardiovascular : Adequate cardiac function Other : HIV negative Not pregnant nurse Fertile patient must use effective contraception No prior malignancy within 5 year except adequately treat nonmelanomatous skin cancer carcinoma situ cervix No history tuberculosis No grade 3 local skin toxicity reaction ( ulceration ) 5 IU great PPD test No active infection require systemic antibiotic , antiviral , antifungal treatment No serious unstable chronic illnesses No psychological , familial , sociological , geographical condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : No prior therapy protein murine origin At least one month since prior immunotherapy No concurrent immunotherapy Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : No concurrent chronic use systemic corticosteroid Radiotherapy : See Disease Characteristics No concurrent radiotherapy include prophylactic cranial irradiation No prior spleen radiotherapy Surgery : No prior surgery SCLC No prior splenectomy Other : No prior secondline therapy SCLC At least one month since prior investigational agent No concurrent chronic use systemic antihistamine nonsteroidal antiinflammatory drug No concurrent immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>limited stage small cell lung cancer</keyword>
</DOC>